RT Journal Article
SR Electronic
T1 Somatostatin Receptor–Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 507
OP 513
DO 10.2967/jnumed.120.249607
VO 62
IS 4
A1 Mirian, Christian
A1 Duun-Henriksen, Anne Katrine
A1 Maier, Andrea
A1 Pedersen, Maria Møller
A1 Jensen, Lasse Rehné
A1 Bashir, Asma
A1 Graillon, Thomas
A1 Hrachova, Maya
A1 Bota, Daniela
A1 van Essen, Martjin
A1 Spanjol, Petar
A1 Kreis, Christian
A1 Law, Ian
A1 Broholm, Helle
A1 Poulsgaard, Lars
A1 Fugleholm, Kåre
A1 Ziebell, Morten
A1 Munch, Tina
A1 Walter, Martin A.
A1 Mathiesen, Tiit
YR 2021
UL http://jnm.snmjournals.org/content/62/4/507.abstract
AB Somatostatin receptor (SSTR)–targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas. Methods: We performed an individual patient data meta-analysis, including all published data on meningioma patients treated with SSTR-targeted PRRT. The main outcomes were toxicity, response to treatment, progression-free survival (PFS), and overall survival (OS). We applied the Kaplan–Meier method to estimate survival probabilities and report incidence rates per 100 person-years. We applied Cox proportional hazards models to determine the effect of covariates. Results: We screened 537 papers and identified 6 eligible cohort studies. We included a total of 111 patients who had treatment-refractory meningioma and received SSTR-targeted PRRT. Disease control was achieved in 63% of patients. The 6-mo PFS rates were 94%, 48%, and 0% for World Health Organization grades I, II, and III, respectively. The risk of disease progression decreased by 13% per 1,000-MBq increase in the total applied activity. The 1-y OS rates were 88%, 71%, and 52% for World Health Organization grades I, II, and III, respectively. The risk of death decreased by 17% per 1,000-MBq increase in the total applied activity. The main side effects comprised transient hematotoxicity, such as anemia in 22% of patients, leukopenia in 13%, lymphocytopenia in 24%, and thrombocytopenia in 17%. Conclusion: To our knowledge, this individual patient data meta-analysis represents the most comprehensive analysis of the benefits of and adverse events associated with SSTR-targeted PRRT for treatment-refractory meningioma. The treatment was well tolerated, achieved disease control in most cases, and showed promising results regarding PFS and OS.